SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

CorMedix is trending as investors await the upcoming earnings report, with community discussion centered on potential revenue growth, DefenCath adoption, and the impact of the pending CMS policy update. Shareholders are actively debating management's recent guidance and the long-term potential for expansion into oncology and TPN markets.

Federal National Mortgage Association is a government-sponsored company, which engages in the provision of liquidity for purchases of homes and financing of multifamily rental housing and refinancing existing mortgages. It operates through the Single-Family and Multifamily segments. The Single-Family segment offers liquidity to the mortgage market and increases the availability and affordability of housing for single families. The Multifamily segment includes guaranty fees on mortgages and on multifamily mortgage loans. The company was founded in 1938 and is headquartered in Washington, DC.

Federal National Mortgage Association

FNMA is seeing high community engagement driven by anticipation surrounding a potential IPO and end of conservatorship, spurred by the President's recent commentary regarding a trillion-dollar valuation for the GSEs. Investors are actively debating the timing of a potential re-listing, with discussions centered on recent analyst upgrades, the actions of high-profile investors like Bill Ackman and Michael Burry, and speculation about the impact of incoming leadership on the GSE framework.

Syndax Pharmaceuticals, Inc. engages in the development of cancer therapies. Its products include Revuforj and Niktimvo. The company was founded by Richard A. Heyman, Eckard Weber, Peter Ordentlich, Ronald M. Evans and Michael Downes on October 11, 2005 and is headquartered in New York, NY.

Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals is trending as the community eagerly anticipates pivotal data readouts at the upcoming ASH meeting, with investors closely watching potential synergy with Incyte for a possible buyout. The sentiment is bolstered by strong Revuforj performance and community belief that the company remains significantly undervalued compared to its oncology peers.

SolarEdge Technologies, Inc. engages in the development of energy technology, which provides inverter solutions. The firm operates through the following segments: Solar and All Other. The Solar segment includes the design, development, manufacturing, and sales of an inverter solution designed to maximize power generation. The All Other segment includes the design, development, manufacturing and sales of UPS products, energy storage products, e-Mobility products, and automated machines. Its products and services include photovoltaic inverters, power optimizers, photovoltaic monitoring, software tools, and electric vehicle chargers. The company was founded by Guy Sella, Lior Handelsman, Yoav Galin, Meir Adest, and Amir Fishelov on August 7, 2006 and is headquartered in Herzliya, Israel.

Solaredge Technologies Inc

SolarEdge is seeing significant market interest as it shifts toward AI-driven data center power infrastructure and solid-state transformer technology, with investors reacting to earnings reports and broader solar sector volatility. The community remains heavily divided between those betting on a long-term turnaround fueled by new product cycles and those focused on bearish technical factors, including ongoing litigation settlements and concerns over the company's profitability and debt levels.

Photronics, Inc. engages in the provision of photomasks, which are quartz or glass plates containing microscopic images of electronic circuits for use in the fabrication of integrated circuits and flat-panel displays. The company was founded by Constantine S. Macricostas in 1969 and is headquartered in Brookfield, CT.

Photronics, Inc.

Photronics is trending as investors digest the impact of its recent earnings miss and soft guidance, which triggered a significant short-term pullback in the stock. While some in the community view the current price as a deep-value opportunity given the company's strong balance sheet and role as a key photomask supplier for AI-driven chip demand, others are wary of the stock's recent technical weakness and the broader volatility across the semiconductor sector.

Tidal Trust II - YieldMax Ultra Option Income Strategy ETF

YieldMax Ultra Option Income Strategy ETF

ULTY is attracting community debate following a 1-for-10 reverse stock split and a strategic shift toward a more diversified portfolio of blue-chip and high-volatility holdings. Investors are actively discussing whether these structural changes and the transition toward NAV stability will successfully counteract previous erosion or if the fund remains a high-risk vehicle primarily for income harvesting.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Moderna is trending following an FDA advisory committee's unanimous endorsement of its experimental mRNA flu vaccine, a development investors view as a pivotal validation of the company's platform and future commercial growth. The community remains heavily divided, with bulls highlighting the company's expanding oncology and infectious disease pipeline, while bears continue to focus on concerns regarding historical product performance and the ongoing debate surrounding public trust in mRNA technology.

Vishay Intertechnology, Inc. engages in the manufacture and distribution of discrete semiconductors and passive electronic components. It operates through the following segments: MOSFET (metal oxide semiconductor field-effect transistor), Diodes, Optoelectronic Components, Resistors, Inductors, and Capacitors. The MOSFET segment offers semiconductors which function as solid state switches to control power. The Diodes segment produces semiconductors which route, regulate, and block radio frequency, analog, and power signals, protect systems from surges or electrostatic discharge damage, and provide electromagnetic interference filtering. The Optoelectronic Components segment includes components that emit light, detect light, or do both. The Resistors and Inductors segment deals with components that impede electric current. The Capacitors segment provides components which store energy and discharge it when needed. The company was founded by Felix Zandman in 1962 and is headquartered in Malvern, PA.

Vishay Intertechnology, Inc.

Vishay Intertechnology is generating significant buzz as it hits fresh 52-week highs, with the community highlighting its strategic position as a foundational supplier for AI infrastructure, robotics, and power management. Investors are actively debating the sustainability of its rapid ascent while tracking institutional accumulation and monitoring technical breakout levels amid broader semiconductor sector momentum.

iShares Trust - iShares Biotechnology ETF

iShares Biotechnology ETF

The iShares Biotechnology ETF is trending as investors pivot into the sector, driven by a combination of clinical breakthroughs, robust M&A activity, and a broader small-cap market rotation. The community is actively debating whether this momentum represents the beginning of a sustainable new bull cycle or a temporary rally, while tracking potential acquisition targets and upcoming regulatory milestones for key companies within the sector.

Amarin Corp. Plc is a pharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. It focuses on the development and commercialization of Vascepa capsules. The company was founded by Geoffrey William Guy on March 1, 1989 and is headquartered in Dublin, Ireland.

Amarin Corp - ADR

Amarin shareholders are actively debating the potential outcomes of the upcoming Supreme Court case involving Hikma Pharmaceuticals, with many viewing the legal battle as a pivotal moment for the company's intellectual property and market position. Simultaneously, there is significant community interest in the timeline for the EMT2 clinical trial results and ongoing speculation regarding potential strategic interest or acquisition, as investors weigh the impact of these developments on the stock's future.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$RXT This has to be institutional buying. Retail would surely have flushed by now...

Ryan R

Phil

StockTwits Web

Rackspace Technology Inc

 This has to be institutional buying. Retail would surely have flushed by now...

SNAK

@CFJHauser it’s definitely institutions. We don’t have that kind of buying power. The AMD, DELL, PLTR associations are a big deal.

StockTwits for iOS

 it’s definitely institutions. We don’t have that kind of buying power. The AMD, DELL, PLTR associations are a big deal.